FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Contract manufacturer FujiFilm Diosynth Biotechnologies, which has been expanding its footprint in Holly Springs, has signed ...

On Tuesday, Fujifilm Diosynth announced a 10-year agreement worth more than $3 billion to make medicines for the New York drugmaker Regeneron in the Triangle. Regeneron is the facility’s third major ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

Fujifilm Diosynth Biotechnologies' bet on its North Carolina biologics facility is paying off, as Regeneron plans to shell ...

Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug ...

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to ...

Regeneron (REGN) announced an expansion of its manufacturing capacity through a new agreement with Fujifilm Diosynth Biotechnologies to ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a positive phase 3 readout. | AstraZeneca and Daiichi Sankyo are gunning to get ...

The agreement is valued at over $3 billion and increases U.S. manufacturing capacity to help ensure patient access to ...

Agreement secures additional U.S. manufacturing capacity to help ensure patient access to medicineHOLLY SPRINGS, N.C., April 23, 2025 -- ...